{"id":"idarubicin-etoposide-cytarbine-teniposide","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Cardiotoxicity"},{"rate":null,"effect":"Infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Idarubicin and etoposide are topoisomerase II inhibitors that prevent DNA unwinding and repair, while cytarabine is a nucleoside analog that incorporates into DNA and disrupts synthesis. Teniposide is also a topoisomerase II inhibitor. Together, these agents work synergistically to induce apoptosis in rapidly dividing leukemic cells.","oneSentence":"This is a combination chemotherapy regimen that uses multiple agents to damage cancer cell DNA and inhibit topoisomerase II, leading to cell death.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:29.145Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute leukemia in pediatric patients (St. Jude protocol-based treatment)"}]},"trialDetails":[{"nctId":"NCT00187083","phase":"PHASE3","title":"A Study of Children With Refractory or Relapsed ALL","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"1997-02","conditions":"Acute Lymphoblastic Leukemia","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"idarubicin, etoposide, cytarbine, teniposide","genericName":"idarubicin, etoposide, cytarbine, teniposide","companyName":"St. Jude Children's Research Hospital","companyId":"st-jude-children-s-research-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination chemotherapy regimen that uses multiple agents to damage cancer cell DNA and inhibit topoisomerase II, leading to cell death. Used for Acute leukemia in pediatric patients (St. Jude protocol-based treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}